Neglected Tropical Disease Treatment Market Size, Share & Trends Analysis Report By Drug Class (Anti-Parasite, Antifungal, Antibiotics, Others), By Disease Type (Leishmaniasis, Schistosomiasis, Lymphatic Filariasis, Chagas Disease, African Trypanosomiasis, Others), By Distribution Channel (Direct Sales, Indirect Sales), By Region, And By Segment Forecasts, 2024-2031

Chapter 1. Methodology and Scope 1.1. Research Methodology 1.2. Research Scope & Assumptions Chapter 2. Executive Summary Chapter 3. Global Neglected Tropical Disease Treatment Market Snapshot Chapter 4. Global Neglected Tropical Disease Treatment Market Variables, Trends & Scope 4.1. Market Segmentation & Scope 4.2. Drivers 4.3. Challenges 4.4. Trends 4.5. Investment and Funding Analysis 4.6. Porter's Five Forces Analysis 4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031 4.8. Global Neglected Tropical Disease Treatment Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031 4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023) 4.10. Use/impact of AI on Neglected Tropical Disease Treatment Industry Trends Chapter 5. Neglected Tropical Disease Treatment Market Segmentation 1: By Drug Class, Estimates & Trend Analysis 5.1. Market Share by Drug Class, 2023 & 2031 5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Drug Class: 5.2.1. Anti-Parasite 5.2.2. Antifungal 5.2.3. Antibiotics 5.2.4. Others Chapter 6. Neglected Tropical Disease Treatment Market Segmentation 2: By Disease Type, Estimates & Trend Analysis 6.1. Market Share by Disease Type, 2023 & 2031 6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Disease Types: 6.2.1. Leishmaniasis 6.2.2. Schistosomiasis 6.2.3. Lymphatic Filariasis 6.2.4. Chagas Disease 6.2.5. African Trypanosomiasis 6.2.6. Others Chapter 7. Neglected Tropical Disease Treatment Market Segmentation 3: By Distribution Channel, Estimates & Trend Analysis 7.1. Market Share by Distribution Channel, 2023 & 2031 7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Distribution Channels: 7.2.1. Direct Sales 7.2.2. Indirect Sales Chapter 8. Neglected Tropical Disease Treatment Market Segmentation 6: Regional Estimates & Trend Analysis 8.1. Global Neglected Tropical Disease Treatment Market, Regional Snapshot 2023 & 2031 8.2. North America 8.2.1. North America Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031 8.2.1.1. US 8.2.1.2. Canada 8.2.2. North America Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031 8.2.3. North America Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Disease Type, 2024-2031 8.2.4. North America Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031 8.3. Europe 8.3.1. Europe Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031 8.3.1.1. Germany 8.3.1.2. U.K. 8.3.1.3. France 8.3.1.4. Italy 8.3.1.5. Spain 8.3.1.6. Rest of Europe 8.3.2. Europe Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031 8.3.3. Europe Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Disease Type, 2024-2031 8.3.4. Europe Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031 8.4. Asia Pacific 8.4.1. Asia Pacific Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031 8.4.1.1. India 8.4.1.2. China 8.4.1.3. Japan 8.4.1.4. Australia 8.4.1.5. South Korea 8.4.1.6. Hong Kong 8.4.1.7. Southeast Asia 8.4.1.8. Rest of Asia Pacific 8.4.2. Asia Pacific Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031 8.4.3. Asia Pacific Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Disease Type, 2024-2031 8.4.4. Asia Pacific Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts By Distribution Channel, 2024-2031 8.5. Latin America 8.5.1. Latin America Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031 8.5.1.1. Brazil 8.5.1.2. Mexico 8.5.1.3. Rest of Latin America 8.5.2. Latin America Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031 8.5.3. Latin America Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Disease Type, 2024-2031 8.5.4. Latin America Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031 8.6. Middle East & Africa 8.6.1. Middle East & Africa Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031 8.6.1.1. GCC Countries 8.6.1.2. Israel 8.6.1.3. South Africa 8.6.1.4. Rest of Middle East and Africa 8.6.2. Middle East & Africa Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031 8.6.3. Middle East & Africa Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Disease Type, 2024-2031 8.6.4. Middle East & Africa Neglected Tropical Disease Treatment Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031 Chapter 9. Competitive Landscape 9.1. Major Mergers and Acquisitions/Strategic Alliances 9.2. Company Profiles 9.2.1. Thermo Fisher Scientific, Inc. 9.2.1.1. Business Overview 9.2.1.2. Key Product/Service Offerings 9.2.1.3. Financial Performance 9.2.1.4. Geographical Presence 9.2.1.5. Recent Developments with Business Strategy 9.2.2. F. Hoffmann-La Roche Ltd. 9.2.3. Omega Diagnostics Group PLC 9.2.4. Abbott 9.2.5. Oscar Medicare Pvt. Ltd. 9.2.6. Merck Ltd. 9.2.7. Genome Diagnostics Pvt. Ltd. 9.2.8. ZeptoMetrix 9.2.9. Bayer AG, 9.2.10. GlaxoSmithKline plc 9.2.11. Novartis AG 9.2.12. Pfizer, Inc. 9.2.13. Eisai Co. Ltd. 9.2.14. Sanofi 9.2.15. Astellas Pharma 9.2.16. Takeda Pharmaceutical Company Limited 9.2.17. Gilead Sciences 9.2.18. Other Market Players